Related Experiment Video
Updated: Jun 2, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Direct-acting antiviral medications for chronic hepatitis C virus infection
Alison B Jazwinski1, Andrew J Muir
1Dr. Jazwinski is a Fellow and Dr. Muir is an Associate Professor in the Division of Gastroenterology and Duke Clinical Research Institute at Duke University Medical Center in Durham, North Carolina.
Abstract:
Treatment of hepatitis C virus has traditionally been difficult because of low rates of treatment success and high rates of treatment discontinuation due to side effects. Current standard therapy consists of pegylated interferon α and ribavirin, both of which have nonspecific and largely unknown mechanisms of action. New therapies are in development that act directly on the hepatitis C virus at various points in the viral life cycle. Published clinical trial data on these therapies are summarized in this paper. A new era of hepatitis C virus treatment is beginning, the ultimate goals of which will be directly targeting the virus, shortening the length of therapy, improving sustained virologic response rates, and minimizing side effects.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Hepatitis
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Viral Hepatitis I: Introduction

